PMID- 29920551
OWN - NLM
STAT- MEDLINE
DCOM- 20190412
LR  - 20190412
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 13
IP  - 6
DP  - 2018
TI  - Adverse events after vaccination among HIV-positive persons, 1990-2016.
PG  - e0199229
LID - 10.1371/journal.pone.0199229 [doi]
LID - e0199229
AB  - Human immunodeficiency virus (HIV) causes immune dysregulation, potentially 
      affecting response to vaccines in infected persons. We investigated if unexpected 
      adverse events (AEs) or unusual patterns of AEs after vaccination were reported 
      among HIV-positive persons. We searched for domestic reports among HIV-positive 
      persons to the Vaccine Adverse Event Reporting System (VAERS) during 1990-2016. 
      We analyzed reports by age group (<19 and >/=19 years), sex, serious or non-serious 
      status, live vaccine type (live versus inactivated), AEs reported, and CD4 
      counts. Of 532,235 reports received, 353 (0.07%) described HIV-positive persons, 
      of whom 67% were aged >/=19 years, and 57% were male; most reports (75%) were 
      non-serious. The most commonly reported inactivated vaccines were pneumococcal 
      polysaccharide (27%) and inactivated influenza (27%); the mostly reported common 
      live virus vaccines were combination measles, mumps, and rubella (8%) and 
      varicella (6%). Injection site reactions were commonly reported (39%). Of 67 
      reports with CD4 counts available, 41 (61%) described persons immunocompromised 
      at time of vaccination (CD4 count <500 cells/mm3), and differed from overall 
      reports only in that varicella was the most common live virus vaccine (4 
      reports). Of 22 reports describing failure to protect against infection, 6 
      described persons immunocompromised at time of vaccination, among whom varicella 
      vaccine was most common (3 reports). Of 66 reports describing live virus 
      vaccines, 7 described persons with disseminated infection: 6 had disseminated 
      varicella, 3 of whom had vaccine strain varicella-zoster virus. Of 18 reported 
      deaths, 7 resulted from disseminated infection: 6 were among immunocompromised 
      persons, 1 of whom had vaccine strain varicella-zoster virus. We identified no 
      unexpected or unusual patterns of AEs among HIV-positive persons. These data 
      reinforce current vaccine recommendations for this risk group. However, 
      healthcare providers should know their HIV-positive patients' immune status 
      because immunocompromising conditions can potentially increase the risk of rare, 
      but severe, AEs following vaccination with live virus vaccines.
FAU - Su, John R
AU  - Su JR
AUID- ORCID: 0000-0002-5897-8031
AD  - Immunization Safety Office, Division of Healthcare Quality Promotion, National 
      Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control 
      and Prevention, Atlanta, GA, United States of America.
FAU - Ng, Carmen
AU  - Ng C
AUID- ORCID: 0000-0003-4219-3907
AD  - Immunization Safety Office, Division of Healthcare Quality Promotion, National 
      Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control 
      and Prevention, Atlanta, GA, United States of America.
FAU - Lewis, Paige W
AU  - Lewis PW
AD  - Immunization Safety Office, Division of Healthcare Quality Promotion, National 
      Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control 
      and Prevention, Atlanta, GA, United States of America.
FAU - Cano, Maria V
AU  - Cano MV
AD  - Immunization Safety Office, Division of Healthcare Quality Promotion, National 
      Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control 
      and Prevention, Atlanta, GA, United States of America.
LA  - eng
PT  - Journal Article
DEP - 20180619
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Measles-Mumps-Rubella Vaccine)
RN  - 0 (Vaccines, Attenuated)
RN  - 0 (Vaccines, Conjugate)
RN  - 0 (Viral Vaccines)
SB  - IM
MH  - Adult
MH  - Drug-Related Side Effects and Adverse 
      Reactions/classification/*epidemiology/pathology
MH  - Female
MH  - HIV/*drug effects/pathogenicity
MH  - HIV Infections/complications/*epidemiology/immunology/virology
MH  - Herpesvirus 3, Human/pathogenicity
MH  - Humans
MH  - Male
MH  - Measles-Mumps-Rubella Vaccine/adverse effects
MH  - Middle Aged
MH  - Vaccines, Attenuated/adverse effects
MH  - Vaccines, Conjugate/adverse effects
MH  - Viral Vaccines/*adverse effects
PMC - PMC6007919
COIS- The authors have declared that no competing interests exist.
EDAT- 2018/06/20 06:00
MHDA- 2019/04/13 06:00
PMCR- 2018/06/19
CRDT- 2018/06/20 06:00
PHST- 2017/06/18 00:00 [received]
PHST- 2018/06/04 00:00 [accepted]
PHST- 2018/06/20 06:00 [entrez]
PHST- 2018/06/20 06:00 [pubmed]
PHST- 2019/04/13 06:00 [medline]
PHST- 2018/06/19 00:00 [pmc-release]
AID - PONE-D-17-23190 [pii]
AID - 10.1371/journal.pone.0199229 [doi]
PST - epublish
SO  - PLoS One. 2018 Jun 19;13(6):e0199229. doi: 10.1371/journal.pone.0199229. 
      eCollection 2018.